Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

By Marc A. F. De Hert, J. Detraux, R. Winkel, Weiping Yu, Christoph U. Correll. Nature Reviews Endocrinology, 2012

1,054 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/8749d096596a5dd0ebfc0cc8db797e9efefb9611

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Psychiatry and Mental health

1. Christoph U. Correll
2. Brendon Stubbs

Citations in the corpus

• Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder (2015, background): “Among the first-generation antipsychotics (FGAs), the so-called low-potency agents, such as chlorpromazine and thioridazine, have higher weight gain potential than the high-potency drugs, such as haloperidol (11,30).”
• Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis (2016, background): “diabetes or a first degree family history of diabetes (40).”